#USA #Class Action #San Francisco #FDA #Corcept Therapeutics

Investor Alert: Corcept Therapeutics (CORT) Faces Class Action Lawsuit

Overview

National shareholder rights law firm Hagens Berman is alerting investors about a critical class action lawsuit involving Corcept Therapeutics Inc. (NASDAQ: CORT). This action is particularly significant after the company's struggles with the FDA and subsequent stock price collapse. Investors with losses throughout the specified class period are urged to take action before the deadline set for April 21, 2026.

Details of the Case

Allegations of Misleading Statements

The lawsuit revolves around the alleged discrepancies between Corcept's public statements regarding its lead drug candidate, relacorilant, and its internal discussions with the FDA. Throughout the class period from October 31, 2024, to December 30, 2025, the company portrayed optimism about relacorilant's potential approval while reportedly withholding critical information from investors.

Key Allegations Include:

1. Insufficient Evidence of Effectiveness: Documents indicate that the FDA warned Corcept in pre-submission meetings during 2024 and 2025 that its clinical data was lacking.
2. Misleading Phase 3 Data: Despite being aware of favorable expectations not aligned with the FDA's views, the company's management persisted in positive narrative regarding the Phase 3 trial results.
3. The CRL Revelation: On December 31, 2025, the company disclosed it had received a Complete Response Letter (CRL) from the FDA, which indicated the drug could not be approved due to an inadequate evidentiary record.

Stock Price Reaction

This disclosure led to a staggering drop in Corcept's stock price from $70.20 at the close of December 30, 2025, to $34.80 by the end of the following day, resulting in nearly $2.5 billion in lost market capitalization. This sudden market reaction highlighted the perceived mismatch between the company’s optimistic projections and the grim reality facing its lead drug candidate.

Taking Action

Hagens Berman encourages affected investors to submit their claims before the April 21, 2026 deadline. Individuals who have incurred losses during the specified class period are especially encouraged to reach out. This initiative aims to secure accountability for those misled during the tumultuous period that led to significant financial losses.

For legal assistance, investors can contact the firm directly at 844-916-0895 or via email at [email protected]

Conclusion

In conclusion, this class action lawsuit against Corcept Therapeutics underscores the critical nature of transparency in pharmaceutical communications. Investors are reminded of their rights and the importance of acting swiftly to protect their interests. Legal representation is available to guide and assist in navigating these complex allegations as the case progresses.

Stay informed and proactive to ensure that your interests as an investor are safeguarded amidst these corporate developments. For more updates, interested parties can visit the Hagens Berman's case page for detailed information.

Contact Information

For those with inside information regarding Corcept Therapeutics, whistleblower programs can offer avenues for reporting that may result in rewards for assisting investigations.

• ---

(Note: This article serves as an informational piece and does not constitute legal advice.)